Daniel joined Ampersand as an Executive Advisor in 2023 and has more than 25 years in senior life science executive roles. He joined the clinical drug development team at Pharmacia & Upjohn in 1996. He later founded TFS (TFS Health Sciences), a global midsized clinical Contract Research Organization serving 250 biopharma customers worldwide. Daniel is the recipient of numerous entrepreneurial achievement awards. In 2010, Daniel received the Swedish National Award as "Man of The Year" by Ernst & Young and in the same year was awarded the title "Entrepreneur of The Year" by Founders Alliance and Grant Thornton. His expertise covers biopharma outsourced services (drug discovery, pre-clinical and clinical) and research technology-enabled services. He is currently serving on the following Board of Directors: Ampersand portfolio company iuvo Bioscience (US), Avance Clinical (Australia), Trialbee (US), PathoQuest (France/US), Scantox (Denmark) and Inhalation Sciences (Sweden). Daniel holds a technical degree in Chemical Engineering and an OPM from Harvard Business School.